Acta Oncologica Lecture. Present status of the use of recombinant human TSH in thyroid cancer management.
Luster
Markus
M
Department of Nuclear Medicine, University of Würzburg, Würzburg, Germany. luster@nuklearmedizin.uni-wuerzburg.de
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D005260:Female; D006801:Humans; D007037:Hypothyroidism / Q000517:prevention & control; D007457:Iodine Radioisotopes / Q000097:blood / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography; D018714:Radiotherapy, Adjuvant; D011994:Recombinant Proteins / Q000627:therapeutic use; D013954:Thyroglobulin / Q000097:blood; D013963:Thyroid Hormones / Q000097:blood; D013964:Thyroid Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000532:radiotherapy; D013972:Thyrotropin / Q000191:economics / Q000493:pharmacokinetics / Q000627:therapeutic use*; D051598:Whole Body Imaging
D007457:Iodine Radioisotopes; D011994:Recombinant Proteins; D013963:Thyroid Hormones; D013972:Thyrotropin; D013954:Thyroglobulin